Fecal DNA screening in colorectal cancer

Canadian Journal of Gastroenterology

Volumn 22, Issue 7, 2008, Pages 631-633

  Richter, Suzanne ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Colonoscopy; Colorectal cancer; DNA testing; FOBT

Indexed keywords

DNA;

ADVANCED CANCER; CANADA; CANCER DIAGNOSIS; CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CLINICAL EFFECTIVENESS; COLONOSCOPY; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA SCREENING; EARLY DIAGNOSIS; FECES ANALYSIS; GENE MUTATION; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INTERMETHOD COMPARISON; MEDICAL SOCIETY; NON INVASIVE MEASUREMENT; OCCULT BLOOD; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 51449084770     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/761208     Document Type: Review

References (17)

1. Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2007. Toronto, Canada, 2007.
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Erratum in 2005;55:259).
3. McLeod R; Canadian Task Force on Preventive Health Care. Screening strategies for colorectal cancer: Systematic review & recommendations. CTFPHC Technical Report #01-2. London: Canadian Task Force of Preventive Health Care, 2001.
4. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71.
5. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
6. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71. (Erratum in 1993;328:1365-71).
7. Hall MJ, Olopade OI. Disparities in genetic testing: Thinking outside the BRCA box. J Clin Oncol 2006;24:2197-203.
8. Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002;137:603-12.
9. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
10. Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007;5:111-7.
11. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the fecal occult blood test, hemoccult. BMJ 1998;317:559-65.
12. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14.
13. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 2004;127:422-7.
14. Wu G, Wang YM, Yen AM, et al. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer 2006;6:136.
15. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: A decision analysis. Gastroenterology 2004;126:1270-9.
16. Kurahashi T, Kaneko K, Makino R, Mitamura K. Colorectal carcinoma with special reference to growth pattern classifications: Clinicopathologic characteristics and genetic changes. J Gastroenterol 2002;37:354-62.
17. Detsky AS. Screening for colon cancer - can we afford colonoscopy? N Engl J Med 2001;345:607-8.